The RESELECT Trial – REscuing bone marrow function in patients with relapsed aplaStic anaEmia and/or bone marrow failure post aLlogeneic stEm Cell Transplantation

2020-2024 (Grant): Rescuing bone marrow function in relapsed acquired Aplastic Anaemia and /or poor graft function post allogeneic bone marrow transplantation, Professor David Ritchie, Melbourne Health.

Clinical trials are important for the testing of new treatments in disease. Clinical trials also can be used to collect patient samples to understand why treatments work or why they do not work. The RESELECT trial will identify and apply novel drug and cellular therapies to benefit patients with the high-risk Bone Marrow Failure Syndrome of relapsed Aplastic Anaemia or bone marrow failure after transplantation (Poor Graft Function – PGF). An initial trial of N-acetylcysteine and atorvastatin has been undertaken with 11 patients enrolled to date and samples collected from all patients. The trial continues to accrue at the anticipated rate, remains of high scientific value and is an important platform for international collaboration. Analysis of the samples will proceed once accrual has been fulfilled.